J&J’s Sjö­gren’s dis­ease drug shows promise in Phase 2, boosts prospects of FcRn as­sets in the au­toim­mune dis­ease

John­son & John­son de­tailed pos­i­tive da­ta from a mid-stage tri­al in peo­ple with Sjö­gren’s dis­ease that, ac­cord­ing to some an­a­lysts, could be an en­cour­ag­ing sig­nal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.